Micro Interventional Devices, Inc. Receives CE Mark Approval for Permaseal(TM)

Disruptive technology simplifies minimally invasive cardiovascular surgery.

NEWTOWN, Pennsylvania, June 7, 2016 /PRNewswire/ -- Micro Interventional Devices, Inc.(TM) [http://www.microinterventional.com/] (MID), the world leader in minimally invasive and catheter-based compliant fixation technology announced today that it received CE Mark approval for the Company's first product: Permaseal(TM) [http://microinterventional.com/permaseal.php] transapical access and closure device. The Permaseal device allows surgeons to access and close the left-ventricle instantaneously, reliably and without suturing the myocardium. Permaseal is the world's first device using compliant soft-tissue PolyCor(TM) anchor technology.

Photo - http://photos.prnewswire.com/prnh/20160606/375925 [http://photos.prnewswire.com/prnh/20160606/375925] Logo - http://photos.prnewswire.com/prnh/20140909/144474 [http://photos.prnewswire.com/prnh/20140909/144474]

Permaseal was validated in the STASIS Clinical Study (Secure Transapical Access and Closure Study) conducted at five European Sites. Results indicated that Permaseal shortened operating time and hospital stay, reduced adverse events including the need for transfusion and reduced 12-month mortality and stroke rates to 0%*. The technology provides a direct, safe and simple, access and closure site for emerging complex structural heart disease procedures including TAVR, TMVR, PFO, and other minimally invasive cardiac procedures.

"The CE Mark approval of Permaseal is a tremendous achievement for MID," said Michael Whitman, MID's Founder, President & CEO. "Permaseal is the first in a series of products designed to replace the need for suturing in structural heart procedures. We are excited that this technology is now available to our European surgeons and their patients."

"In the near future, PolyCor and MyoLast(TM) technologies will be utilized in a broad range of proprietary, catheter-based products, addressing unmet needs in tricuspid repair, mitral repair and mitral valve fixation," added Whitman. "MID's technology platform enables open-surgical procedures to be performed percutaneously."

Permaseal is currently the only transapical access and closure device available for commercial use in the EU. FDA clearance to market Permaseal is pending.

*Data on file.

About Micro Interventional Devices, Inc. (MID):

MID is the world leader in compliant fixation technology addressing unmet needs in structural heart disease.

Company Contact:Micro Interventional Devices, Inc.Katherine WhitmanProduct Director215 600 1270info@microinterventional.com [mailto:info@microinterventional.com]www.microinterventional.com [http://www.microinterventional.com/]

Photo: https://photos.prnewswire.com/prnh/20160606/375925http://photos.prnewswire.com/prnh/20140909/144474AP PhotoExpress Network: PRN707003

Micro Interventional Devices, Inc.

Web site: http://www.microinterventional.com/

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234